Example: Heart Attack

Clinical Trials on Lymphangioleiomyomatosis

Total 41 results

    • NCT01484236
      Recruiting
      National Lymphangioleiomyomatosis Registry, France
      Conditions: Lymphangioleiomyomatosis
    • NCT02009241
      Completed
      Pulmonary Rehabilitation in Lymphangioleiomyomatosis
      Conditions: Lymphangioleiomyomatosis
    • NCT03253913
      Unknown status
      Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
      Conditions: Lymphangioleiomyomatosis
    • NCT03062943
      Recruiting
      A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
      Conditions: Lymphangioleiomyomatosis
    • NCT02116712
      Completed
      The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
      Conditions: Pulmonary Lymphangioleiomyomatosis
    • NCT00414648
      Unknown status
      Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)
      Conditions: Lymphangioleiomyomatosis
    • NCT01799538
      Recruiting
      Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
      Conditions: Lymphangioleiomyomatosis
    • NCT02737202
      Terminated
      Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
      Conditions: Pulmonary Lymphangioleiomyomatosis
    • NCT01353209
      Completed
      Trial of Aromatase Inhibition in Lymphangioleiomyomatosis
      Conditions: Lymphangioleiomyomatosis
    • NCT01059318
      Completed
      A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
      Conditions: Lymphangioleiomyomatosis
    • NCT03150914
      Recruiting
      Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
      Conditions: LAM; Lymphangioleiomyomatosis
    • NCT01687179
      Completed
      Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
      Conditions: Lymphangioleiomyomatosis
    • NCT00960895
      Completed
      Pulmonary Hypertension in Lymphangioleiomyomatosis
      Conditions: Lymphangioleiomyomatosis; Pulmonary Hypertension
    • NCT04184193
      Completed
      Benefits of Pulmonary Rehabilitation in Patients With Severe Lymphangioleiomyomatosis (LAM)
      Conditions: Lymphangioleiomyomatosis; LAM; Pulmonary Rehabilitation
    • NCT00989742
      Completed
      Doxycycline In Lymphangioleiomyomatosis (LAM)
      Conditions: Lymphangioleiomyomatosis; Tuberous Sclerosis
    • NCT00790400
      Completed
      Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
      Conditions: Tuberous Sclerosis Complex (TSC); Lymphangioleiomyomatosis (LAM)
    • NCT02432560
      Active, not recruiting
      Safety and Durability of Sirolimus for Treatment of LAM
      Conditions: Lymphangioleiomyomatosis
    • NCT03304678
      Recruiting
      Discovery of Sirolimus Sensitive Biomarkers in Blood
      Conditions: Lymphangioleiomyomatosis
    • NCT03131999
      Completed
      LAM Pilot Study With Imatinib Mesylate
      Conditions: Lymphangioleiomyomatosis
    • NCT02325505
      Recruiting
      Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma
      Conditions: Tuberous Sclerosis; Lymphangioleiomyomatosis; Angiomyolipoma
    • NCT02061397
      Completed
      Safety of Simvastatin in LAM and TSC
      Conditions: Lymphangioleiomyomatosis; Tuberous Sclerosis Complex
    • NCT04388371
      Enrolling by invitation
      Glutamine PET Imaging in LAM
      Conditions: Lymphangioleiomyomatosis (LAM)
    • NCT03193892
      Unknown status
      A National Registry on Chinese Patients With Lymphangioleiomyomatosis
      Conditions: Pulmonary Function
    • NCT02484664
      Completed
      COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
      Conditions: Lymphangioleiomyomatosis (LAM)
    • NCT00490789
      Unknown status
      Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
      Conditions: Tuberous Sclerosis; Lymphangioleiomyomatosis
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations